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Abstract: The public sector scale-up of antiretroviral therapy (ART)
in South Africa commenced in 2004. We aimed to describe the hospital-
level disease burden and factors contributing to morbidity and mortality
among hospitalized HIV-positive patients in the era of widespread ART
availability.
Between June 2012 andOctober 2013, unselected patients admitted to
medical wards at a public sector district hospital in Cape Town were
enrolled in this cross-sectional study with prospective follow-up. HIV
testingwas systematically offeredandHIV-infectedpatientswere system-
atically screened for TB. The spectrum of admission diagnoses among
HIV-positive patients was documented, vital status at 90 and 180 days
ascertained and factors independently associated with death determined.
Among 1018 medical admissions, HIV status was ascertained in
99.5%: 60.1% (n¼ 609) were HIV-positive and 96.1% (n¼ 585) were
enrolled. Of these, 84.4% were aware of their HIV-positive status before
admission. ART status was naive in 35.7%, current in 45.0%, and
interrupted in 19.3%. The most frequent primary clinical diagnoses were
newly diagnosed TB (n¼ 196, 33.5%), other bacterial infection (n¼ 100,
17.1%), and acquired immunodeficiency syndrome (AIDS)-defining ill-
nesses other than TB (n¼ 64, 10.9%). By 90 days follow-up, 175 (29.9%)
required readmission and 78 (13.3%) died. Commonest causes of death
were TB (37.2%) and other AIDS-defining illnesses (24.4%). Indepen-
dent predictors of mortality were AIDS-defining illnesses other than TB,
low hemoglobin, and impaired renal function.
HIV still accounts for nearly two-thirds of medical admissions in this
South African hospital and is associated with highmortality. Strategies to
improve linkage to care, ART adherence/retention and TB prevention are
key to reducing HIV-related hospitalizations in this setting.
(Medicine 94(50):e2269)
Abbreviations: AIDS = acquired immunodeficiency syndrome,
CD = cluster of differentiation, HIV = human immunodeficiency
virus, IQR = interquartile range, MOD = major organ dysfunction,
NCD = noncommunicable disease, NHLS = National Health
Laboratory Service, TB = tuberculosis, WHO = World Health
Organization.
INTRODUCTION
S outh Africa has the largest human immunodeficiency virus(HIV) epidemic in the world with an estimated 6.4 million
people living with HIV infection.1 The public sector antiretro-
viral (ART) programme was launched in 2004.2 Over the past
decade there has been an unprecedented scale-up of the pro-
gramme with more than 2.6 million people having initiated
ART.3,4 ART is now available free of charge at 3736 public
health facilities across South Africa to those eligible based
on clinical and cluster of differentiation (CD)4 count criteria.
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HIV-related mortality has decreased5 and life expectancy has
increased to approximately 80% of normal life expectancy.6 It is
estimated that 2.2million deaths will have been averted by 2016.7
In developed countries, the availability of triple-drug ART
in the mid-1990s heralded dramatic reductions in acquired
immunodeficiency syndrome (AIDS)-defining illnesses and
hospital admissions for HIV-related opportunistic infec-
tions.8–14 In South Africa, prior to widespread ART avail-
ability, HIV/AIDS accounted for approximately 50% of
medical ward admissions in public sector hospitals.15,16 A
recent systematic review and meta-analysis has summarized
data on causes of hospital admission among children and adults
living with HIV globally: AIDS-related illnesses (including
tuberculosis [TB]) and bacterial infections were the 2 com-
monest causes of adult HIV admissions in all geographical
regions and the most common causes of hospital mortality.17
However, a decade into widespread ART scale-up, little is
known about the impact of the ART programme on adult
HIV-related hospitalizations and outcomes at the level of public
sector hospitals in South Africa.
Thus, we sought to define the hospital-level epidemiology
of HIV infection a decade after the launch of the world’s largest
public sector ART programme. We aimed to determine the
proportion of hospital admissions related to HIV infection,
admission diagnoses, to describe patients’ prior access to
HIV treatment services, and to determine the associated
mortality and factors that contributed to mortality. In the
discussion, based on our findings, we explore reasons why in
the presence of ART availability a substantial number of
admissions and deaths continue to occur.
METHODS
Setting and Patients
This cross-sectional study with prospective follow-up was
conducted between 6th June 2012 and 4th October 2013, at G.F.
Jooste Hospital. This 200-bed adult public sector district hos-
pital is located in the Western Cape province of South Africa
and serves township communities of around 1.3 million people.
In these communities, the HIV seroprevalence approximates to
the national estimate; the antenatal HIV seroprevalence in
Khayelitsha in 2013 was 34.4%.18 The vast majority of people
living in these communities rely on the public health system for
hospital admission. ART has been freely available in the public
sector since April 2004.2 During the initial study period (June
2012–April 2013), patients were eligible for ART if their CD4
count was <200 cells/mL (or <350 cells/mL if they were preg-
nant or had TB) or if they had any World Health Organization
(WHO) stage 4 illness. The criteria expanded in April 2013 to
include all with CD4 counts350 cells/mL or WHO stages 3 or
4 disease. By December 2013, it is estimated that 41,806 adult
patients were on ART in 20 public sector clinics in the referral
area of this hospital (Western Cape Government, unpublished).
ART coverage was regarded as above average compared to
national coverage in these communities.19
The primary aim of the parent study was to assess the
diagnostic yield of performing routine microbiological screen-
ing for TB among unselected HIV-infected patients admitted to
the medical wards. The sample size was set in order to deter-
mine the prevalence of newly diagnosed microbiologically
confirmed TBwith adequate precision (95% confidence interval
of þ/5%) in the parent study.20 Here, we report a secondary
analysis focused on overall admission diagnoses and outcomes.
Adult patients aged 18 years were recruited on 4 days of each
week from the 2 medical wards. To avoid selection bias, on
recruitment days the study coordinator recorded from the ward
register all medical admissions in a 24-hour period. All patients
with previously negative or undocumented HIV status were
offered HIV counseling and testing using 2 rapid tests: ABON
HIV1/2/0/Tri-line HIV rapid test (Alere Inc., Waltham, MA) and
Determine HIV-1/2 rapid test (Alere Inc.). All patients testing
HIV-positive and all those documented previously to be HIV-
positive were invited to participate. The study was approved by
the Human Research Ethics Committees of the University of
Cape Town and the London School of Hygiene and Tropical
Medicine. All participants provided written informed consent.
This study is reported in conformity with the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
statement checklist for observational studies.
Procedures
Demographic and clinical details were recorded on stan-
dardized forms. The research team systematically obtained
sputum, urine, and blood specimens for TB investigations in
the first 24 hours of admission.20 Numerous additional samples
for TB investigations were obtained by ward teams during the
admission period. Results of TB tests conducted up to 1 year
prior to admission at primary care clinics were obtained from
the National Health Laboratory Service (NHLS) electronic
records. The ward teams undertook other investigations as
directed by the clinical scenario. Biochemistry, hematology,
and microbiological tests were conducted at the NHLS.
Data Acquisition and Definitions
The admission diagnoses were extracted from patients’
medical records, and this was supplemented with additional
data from the NHLS laboratory results database. Two investi-
gators (GM and ADK) reviewed all the diagnostic information
obtained and assigned each participant into one of the following
mutually exclusive, prespecified categories for their primary
clinical diagnosis by consensus: new TB diagnosis (took
priority over other diagnoses); clinical deterioration of TB cases
during treatment (included the following underlying causes:
poor adherence, drug resistant TB, TB-associated immune
reconstitution inflammatory syndrome, hemoptysis, and pneu-
mothorax); AIDS-defining illnesses other than TB (included
opportunistic infections and AIDS-related malignancies); non-
communicable diseases (NCDs, included non-AIDS cancer,
diabetes, hypertensive complications, heart failure, and
asthma); other bacterial infection (including pneumonia and
dysentery); venous thromboembolism; drug-related (adverse
effects or overdose); psychiatric illness; major organ dysfunc-
tion (MOD) not attributable to one of the above categories
(included renal and liver failure, bone marrow dysfunction,
seizures, and stroke); or other. In a separate categorization,
all patients with a neurological diagnosis across all the primary
clinical diagnoses were identified.
A new TB diagnosis was defined by detection of Myco-
bacterium tuberculosis from any clinical sample using culture
or Xpert MTB/RIF or a physician’s decision to start of full
course of empiric TB treatment. This category (new TB diag-
nosis) included not only all diagnoses made during the admis-
sion period, but also diagnoses within 7 days prior to the index
admission (at any hospital or clinic).
Patients’ ART status was classified (naive, current, or
interrupted) on the day of admission. Vital status 90 and 180
days after the admission date was determined using patient case
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notes and the medical ward register in addition to 5 electronic
health record databases that were searched systematically by
hospital folder numbers as well using different combinations of a
patients’ identifying information. Additional patient deaths were
ascertained by cross-referencing patient identification numbers
with death certificates through the South African Department of
Home Affairs database. The multiple databases were cross-
referenced for consistency in patient outcomes and any discre-
pancieswere resolved. For patients inwhomvital status could not
be ascertained from one of the 8 data sources, the outcome was
defined as ‘‘could not be traced.’’ AnHIVviral load<400 copies/
mL during admission was regarded as virologically suppressed.
Estimated glomerular filtration rate was calculated using the
Modification of Diet in Renal Disease study equation.21
Data Analysis
Medians were compared using either Wilcoxon rank-sum
tests or Kruskal–Wallis tests, and means were compared using
unpaired t-tests. Chi-squared and Fisher exact tests were used to
compare proportions. The main survival analyses that we pre-
sent focused on 90-day mortality, since deaths within this time
period most likely related to the index admission diagnosis and
follow-up data were very complete up to this time-point (95%).
Patients with unknown 90-day outcomes were censored on the
date they were last seen alive in a health care setting. Kaplan–
Meier survival analyses compared 90-day mortality based on
primary clinical diagnosis, ART category, and virological sup-
pression; the log-rank test was used to compare groups. A Cox
proportional hazards model was constructed to identify indepen-
dent predictors ofmortality.All variables in the univariablemodel
meeting a cut-off of P 0.1 and age (an a priori risk factor) were
included in the multivariablemodel. Schoenfeld’s global test was
used to test the proportional hazards assumption.22 All statistical
tests were 2-sided at a¼ 0.05.
RESULTS
The HIV status of 1013 of 1018 (99.5%) unselected new
admissions to the adult medical wards was ascertained. Of the
609 patients (60.1%) with a positive HIV test, 585 (96.1%) were
enrolled (Fig. 1).
Reasons for Admission
The most frequent primary clinical diagnosis was newly
diagnosed TB (n¼ 196, 33.5%) followed by other bacterial
Medical admissions n=1018
HIV-posive 
n=609 (60.1%)
HIV-negave (n=404)
Enrolled
n=585 (96.1%)
Losses prior to enrolment:
-Died (n= 1)
-Transferred-out (n=5) 
-Refused/uncooperave/confused (n=15)
-Readmissions (n=3)
HIV status known 
n=1013 (99.5%)
HIV status unknown (n=5)
Alive at 90 days
n=476 (81.4%)
Died within 90 days
n=78 (13.3%)
Not traced at 90 days
n=31 (5.3%)
Primary clinical diagnosis:
-New TB: 196 (33.5%)
-Bacterial infecon: 100 (17.1%)
-AIDS-deﬁning illness (other than TB): 64 (10.9%)
-Major organ dysfuncon: 59 (10.1%)
-Known TB and worsening: 42 (7.2%)
-Other diagnosis: 35 (6.0%)
-Venous thromboembolism: 31 (5.3%)
-Drug-related: 24 (4.1%)
-Non-communicable disease: 22 (3.8%)
-Psychiatric: 9 (1.5%)
-Primary diagnosis could not be made: 3 (0.5%)
FIGURE 1. Study profile: this flow diagram shows the numbers of patients screened for the study, reasons for exclusion, number enrolled,
primary clinical diagnoses, and 90-day outcomes.
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infection, AIDS-defining illnesses other than TB, MOD, and
worsening of known TB (Fig. 1). There were 88 patients
(15.0%) with neurological diagnoses, most frequently TB
meningitis (n¼ 27) and cryptococcal meningitis (n¼ 18).
A total of 44% of admissions (n¼ 255) were directly
related to TB: 196 with a new TB diagnosis, 42 with clinical
deterioration during treatment for TB, and 17 with an adverse
reaction to TB treatment (16 of these were drug-induced liver
injury). An additional 78 patients (13.3%) were receiving TB
treatment at admission, but the reason for index admission was
another diagnosis such as other bacterial infection or AIDS-
defining illness. Thus, 56.9% (n¼ 333) of all patients had either
a primary or secondary diagnosis of TB. Of 196 patients with a
new TB diagnosis, 160 (81.6%) were confirmed by either
culture of M. tuberculosis or Xpert MTB/RIF on a range of
clinical samples. Of the 36 patients without a confirmed
microbiological diagnosis, 14 were diagnosed with TB menin-
gitis based on clinical findings and cerebrospinal fluid analysis,
and most of the others were started on empiric TB treatment in
primary care immediately prior to admission.
HIV Diagnosis and ART Exposure
Of the 585 HIV-infected patients, 93 (15.9%) had newHIV
diagnoses made during the index admission and their median
CD4 count was 73 cells/mL (interquartile range [IQR] 40–188).
Overall, 209 (35.7%) patients were ART-naive; 376 (64.3%)
were ART-experienced with 263 currently receiving ART
(45.0%) and 113 (19.3%) having interrupted therapy. Most
baseline characteristics did not differ by ART exposure
(Table 1). However, the median CD4 count was lowest in those
who had interrupted (median 71 cells/mL; and 62.8% of these
patients had CD4< 100 cells/mL) compared with those who
TABLE 1. Baseline Characteristics for 585 Patients With HIV Infection Admitted to Medical Ward
All Patients
n¼ 585
(100%)
ART-Naive
n¼ 209
(35.7%)
Current
ART Use
n¼ 263
(45.0%)
ART
Interrupted
n¼ 113
(19.3%) P-Value
Patient characteristics
Age, median (IQR) 35.3 (28.9–41.4) 34.1 (28.1–40.8) 35.9 (29.8–41.7) 34.9 (29.2–41.1) 0.294
Female 338 (57.8%) 114 (54.6%) 160 (60.8%) 64 (56.6%) 0.375
New HIV diagnosis 93 (15.9%) 93 (44.5%) - –
ART status
Received a second-line regimen 38 (6.5%) – 19 (7.2%) 19 (16.8%) <0.001
If ART experienced, duration since
started ART (years), median (IQR)
1.9 (0.4–4.7) – 1.1 (0.2–2.9) 4.7 (2.4–6.6) <0.001
Proportion taking ART for <90 days
(if currently receiving ART)
67 (26.5%) – 67 (26.5%) – –
Past history of TBa 263 (45.1%) 53 (25.5%) 129 (49.2%) 81 (71.7%) <0.001
Hemotological tests
Hemoglobin, g/dLb 9.5 (7.6–11.3) 9.1 (7.0–11.4) 9.8 (8.0–11.5) 9.4 (7.7–11.0) 0.118
Moderate/severe anemia

399 (69.0%) 143 (69.4%) 172 (66.2%) 84 (75.0%) 0.236
White blood cell count, cells/mLc 6.9 (4.6–10.1) 7.2 (4.4–10.4) 7.0 (5.1–9.7) 6.6 (4.3–10.2) 0.754
Platelets, platelets/mLd 260 (188–355) 246 (176–330) 280 (207–379) 246 (186–338) 0.003
CD4 cell count, cells/mLa
Median (IQR) 134 (53–275) 123 (52–273) 173 (85–330) 71 (31–175) <0.001
0–99 234 (40.1%) 89 (42.8%) 74 (28.2%) 71 (62.8%) <0.001
100–199 137 (23.5%) 48 (23.1%) 71 (27.1%) 18 (15.9%)
200 212 (36.4%) 71 (34.1%) 117 (44.7%) 24 (21.2%)
HIV viral load, log copies/mLe
Median (IQR) 4.2 (1.6–5.5) 5.3 (4.6–5.9) 2.4 (1.6–3.8) 4.7 (3.1–5.8) <0.001
Virologically suppressed (<400 copies/mL) 175 (30.8%) 9 (4.5%) 142 (54.8%) 24 (21.8%) <0.001
C-reactive proteinf
Median 70 (24–136) 71 (21–138) 66 (24–133) 82 (24–170) 0.653
Creatinine, mmol/La
Median (IQR) 68 (52–93) 71 (55–101) 64 (50–85) 68 (52–94) 0.013
Estimated glomerular filtration rate, mL/min/1.73m2ay
<30 39 (6.7%) 18 (8.6%) 16 (6.1%) 5 (4.4%) 0.323
30–59 49 (8.4%) 21 (10.1%) 17 (6.5%) 11 (9.7%)
60 495 (84.9%) 170 (81.3%) 228 (87.4%) 97 (85.8%)
Data are median (IQR) or number (%). Percentages are column percentages. ART¼ antiretroviral therapy, HIV¼ human immunodeficiency virus,
IQR¼ interquartile range, TB¼ tuberculosis. a2 Results missing,b7 results missing,c10 results missing, d13 results missing, e16 results missing, f25
results missing.
Moderate or severe anemia was defined using WHO criteria (hemoglobin< 11.0 g/dL for both males and females).
yEstimated glomerular filtration rate was calculated with the Modification of Diet in Renal Disease (MDRD) Study equa-
tion¼ 175 (creatinine)1.154 (Age)0.203 (0.742 if female) (1.212 if African).
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wereART-naive and those currently onART(Table 1). Themedian
ART duration for patients currently receiving ART was 1.1 years
(IQR¼ 0.2–2.9), 26.5% had started ART within the preceding 90
days. Virological suppression was not significantly associated with
duration of ART, the proportion virologically suppressed among
those onART for<6months was 49.5%, for 6 to 12months 58.6%
and for those 12 months on ART 58.0% (P¼ 0.40). A higher
proportion of patients who had interrupted ART had been on
second-line ART comparedwith those currently onART (Table 1).
Cascade of Care
Of the 585 patients, HIV viral load results were available
for 569 (97.3%) and these data were used to help classify these
patients in the cascade of HIV care (Fig. 2). There was a
substantial fall-off at each step of the cascade of HIV care
pathway. Overall, just 25.0% (n¼ 142) were currently taking
ART and were virologically suppressed.
Patients Currently Taking ART and Virologically
Suppressed
These 142 patients who were virologically suppressed
represented 54.8% of those currently on ART and who had a
viral load result. The median CD4 count in these patients was
251 cells/mL (IQR 136–449), and their median duration on
ART was 1.1 years (IQR 0.3–3.6). The most frequent reasons
for admission in these patients were newly diagnosed TB
(23.2%), other bacterial infection (17.6%), MOD (15.5%),
and venous thromboembolism (10.6%). Noninfectious reasons
for admission tended to be more frequent in these patients
compared to those who were currently on ART but not vir-
ologically suppressed (Supplementary Table 1).
Outcomes and Predictors of Mortality
In-hospital mortality at G.F. Jooste Hospital during the
index admission was 5.3% (n¼ 31). At 90 days of follow-up, 78
patients had died (13.3%) and 31 (5.3%) could not be traced.
The 90-day cumulative mortality varied according to primary
clinical diagnosis (Supplementary Table 2): for patients with
newly diagnosed TB it was 10.7%, for those with known TB
deteriorating on TB treatment it was 9.5%, for those with other
AIDS-defining illnesses it was 29.7%, and for those with NCDs
it was 27.3%.
Fig. 3A shows Kaplan–Meier analysis of 90-day mortality,
demonstrating significantly higher mortality in those with a
non-TB AIDS-defining diagnosis compared with other diag-
noses (P< 0.001). Among patients with a neurological diag-
nosis 10/88 (11.4%) died by 90 days and of those with an AIDS-
related neurological diagnosis 6/24 (25.0%) died by 90 days. In
Kaplan–Meier analyses, there was no significant difference in
mortality according to ART-status at the time of admission
(Fig. 3B, P¼ 0.913) or by HIV viral load suppression status on
the day of admission (Fig. 3C, P¼ 0.759). Of the 78 deaths by
90 days, 37.2% were attributable to TB (new or deteriorating
TB or adverse reaction to TB treatment), 24.4% to AIDS-
defining conditions other than TB, and 19.2% to major organ
dysfunction or NCDs (Supplementary Figure).
Factors associated with 90-day mortality were analyzed in
a Cox regression model (Table 2). Having a diagnosis of an
AIDS-defining illness other than TB, lower hemoglobin levels,
and lower glomerular filtration rates were independently associ-
ated with mortality. CD4 count did not independently
predict mortality.
Patients frequently required hospital readmission follow-
ing discharge: 29.9% (n¼ 175) were readmitted to hospital at
least once within 90 days of the index admission. Of patients
currently on ART, 30.8% (n¼ 81) required readmission com-
pared to 30.1% (n¼ 63) and 27.4% (n¼ 31) of those who were
not on ART or had interrupted ART, respectively (P¼ 0.81). A
similar proportion of virologically suppressed patients were
readmitted compared to those without virological suppression
but receiving ART (28.9% vs 31.6%; P¼ 0.63).
100
84.4
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FIGURE 2. Cascade of care at G.F. Jooste Hospital among all HIV-infected patients with a viral load result available (n¼569). These
categories relate to patients’ status in the care cascade on the day of admission. ‘‘HIV status known’’ refers to patients whowere diagnosed
with HIV prior to the index admission.
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Outcomes at 180 Days
By 180 days, 104 (17.8%) had died and 50 (8.6%) could
not be traced. The main primary clinical diagnoses among those
who died were TB-related (n¼ 41, 39.4%), other AIDS-defin-
ing illnesses (n¼ 22, 21.2%), and major organ dysfunction/
NCD (n¼ 20, 19.2%). In the Cox regression model, the same
factors were also independently associated with 180-day
mortality: having a diagnosis of an AIDS-defining illness other
than TB, lower hemoglobin levels, and lower glomerular filtra-
tion rates (data not shown).
DISCUSSION
The public health benefit of ART in South Africa has been
enormous with greatly increased life expectancy.5,6 Nonetheless,
despite widespreadART availability, the burden of HIV-associated
morbidity and mortality at public sector hospitals remains substan-
tial with cost and resource implications.23 Over 60% of medical
admissions at our hospital were HIV-related. Mortality at 90 days
was13.3%amongHIV-infectedpatients; likely anunderestimate as
approximately 5% could not be traced.24,25 One-third required
readmission within 90 days, reflecting their clinical complexity
and resulting inadditional utilizationof scarcehealthcare resources.
A better understanding of reasons for this ongoing high number of
HIV-related admissions is needed for designing interventions that
address contributing comorbidities and health system factors.
At this same hospital in 2003 (prior to widespread ART
scale-up), 43% of medical admissions were confirmed or
suspected to be HIV-infected.15 Although HIV testing was
not universal during this earlier study (limiting comparability),
it suggests that despite increasing ART availability in commu-
nities surrounding the hospital for a decade, the proportion of
HIV-related admissions has not decreased. This contrasts
experiences in Europe and North America where HIV became
a condition largely managed in outpatient settings upon intro-
duction of triple-drug ART in the mid-1990s.10,12–14 A number
of explanations for this difference are plausible, including
health system issues and the different spectrum of opportunistic
infections and other morbidities affecting HIV-infected indi-
viduals. The increasing absolute number of patients progressing
to advanced HIV-related immunosuppression in the hospital’s
referral area over the period likely also contributed.
Several ‘‘cracks’’ in the cascade of care contributed to the
majority of admitted patients not being virologically suppressed
(Fig. 2). In 15.6% of patients, their HIV diagnosis had not been
made prior to admission, demonstrating that HIV testing is not
yet detecting all those infected before the onset of serious HIV-
related morbidity. The majority of HIV diagnoses had been
previously been made, indicating that these patients had at least
initial contact with outpatient healthcare services. Of patients
with an HIV diagnosis made prior to admission (n¼ 480),
23.1% were ART naive. There are several possible reasons
TABLE 2. Cox Regression of Risk Factors for 90-day Mortality Among all Patients (n¼572 in Final Model With Complete Results)
Variable
Unadjusted
HR (95%CI) P-Value
Adjusted HR
(95%CI) P-Value
Age, years, for each unit increase

1.00 (0.98–103) 0.783 1.00 (0.98–1.03) 0.789
Gender
Male 1.0
Female 1.00 (0.64–1.57) 0.999
HIV status
Previously known 1.0 0.160
New diagnosis 1.49 (0.87–2.56)
ART status
Current 1.0 0.914
Naive 1.05 (0.64–1.74)
Interrupted 1.14 (0.63–2.06)
Past history of TBa
No 1.0 0.877
Yes 0.97 (0.62–1.51)
Primary clinical diagnosis
Other 1.0 0.001 1.0 0.004
New TB 1.14 (0.61–2.12) 0.89 (0.47–1.67)
TB deteriorator 1.04 (0.35–3.05) 0.92 (0.31–2.73)
AIDS-defining illness (other than TB) 3.53 (1.87–6.67) 2.98 (1.54–5.77)
Major organ dysfunction/noncommunicable disease 2.02 (1.03–3.98) 1.56 (0.77–3.18)
Hemoglobin, g/dL, for each one unit decreaseb 1.15 (1.06–1.25) 0.001 1.14 (1.04–1.24) 0.005
White cell count, cells/mL, for each unit increasec 0.99 (0.95–1.03) 0.467
CD4 count, cells/mL, for each 50 decreasea 1.10 (1.02–1.18) 0.005 1.06 (0.98–1.15) 0.122
Log HIV viral load, copies/mL, for each one
unit increased
1.00 (0.87–1.14) 0.943
eGFR for each 10 unit decrease, mL/min/1.73m2 1.07 (1.03–1.11) <0.001 1.05 (1.01–1.09) 0.015
AIDS¼ acquired immunodeficiency syndrome, ART¼ antiretroviral therapy, CD¼ cluster of differentiation, CI¼ confidence interval,
eGFR¼ estimated glomerular filtration rate, HIV¼ human immunodeficiency virus, HR¼ hazard ratio, TB¼ tuberculosis. a2 values missing, b7
values missing, c10 values missing, and d16 values missing.
A priori risk factor.
Schoenfeld’s global test¼ 0.781.
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for this: including recent HIV diagnosis, ART refusal, ART
initiation delayed, or ineligibility based on contemporary guidelines
at HIV diagnosis and subsequent inadequate follow-up. An
additional 19.3% of patients (110/569) had previously received
ART, but had interrupted therapy. Among those currently on ART,
nearly one halfwere not virologically suppressed, suggesting recent
ART initiation, poor adherence, and/or ART resistance.
Strikingly, 25% of HIV-infected patients were on effective
ART with a suppressed viral load and yet developed conditions
requiring hospitalization. One explanation is that a substantial
proportion of patients in resource-limited settings still com-
mence ART with low CD4 counts26 and remain at high risk for
opportunistic infections during early ART. For similar reasons,
if patients start ART with low CD4 counts and later interrupt,
the CD4 count drops to pre-ART levels rapidly putting them at
high risk of infectious complications.27 Historically, in com-
munities served by this hospital, patients started ART with very
low CD4 counts.28,29 In the present study, the median current
CD4 count in those who had interrupted ART was 71 cells/mL.
Our findings suggest that much of the contemporary hospi-
tal-level morbidity is not at the ‘‘front end’’ of the cascade (prior
to HIV diagnosis and ART), but at the ‘‘back end’’ in patients
failing virologically while on ART or disengaging from ART
services – a different scenario to the years before andduring early
ART scale-up.30–32 One-fifth of HIV-related admissions were of
patientswhohad interruptedART; these patients had startedART
a median of 4.7 years previously. A systematic review reported
29.5% median attrition from African ART clinics by 36 months,
with 59% of this attrition attributed to loss to follow-up.33
Contributing factors may include patients’ perception of their
health, life events, financial and occupation issues, and experi-
ences at their clinic.33–36 As clinic patient numbers have grown,
retaining patients in ART care has been challenging.37,38 A
related problem is poor adherence on ART; if detection of
virological failure is delayed, patients may experience clinical
deterioration needing hospital admission prior to appropriate
switch to second-line therapy. Some patients have ongoing
adherence problems on second-line, remaining unsuppressed.
Strategies to monitor and optimize adherence and retention are
critical for maximizing ARTs public health benefit. ‘‘Adherence
clubs’’ in Khayelitsha are a novel and promising strategy.39,40
An important reason for the differential effect of ART on
hospitalization in this setting compared with well-resourced
settings is the high prevalence of co-infections. TB contributed
directly to 43.6% of admissions, and 37.2% of deaths within 90
days. Patients not on ART or on ART with low CD4 counts are
particularly susceptible, but even in patients on ART in these
communities, the risk of TB remains considerably elevated
compared to that of HIV-negative people, being 4-fold higher
even with CD4 counts >700 cells/mL on ART.41 In our study,
6.2% (n¼ 12) of patients with newly diagnosed TB had a CD4
count between 350 and 499 cells/mL, and a further 5.6%
(n¼ 11) had a CD4 count 500 cells/mL. TB was also the
commonest reason for admission in those with suppressed viral
load. In a recent systematic review of post-mortem studies, TB
was reported to account for approximately 40% of facility-
based HIV-related adult deaths in resource-limited settings.42
AIDS-related conditions other than TB accounted for 1 in 10
admissions, yet were an independent predictor of mortality
accounting for one-quarter of deaths.
What are the messages for health system planners from our
findings? First, even with successful ART scale-up in sub-
Saharan Africa as in the Western Cape province,43 HIV-related
hospitalizations remain very common. Second, interventions to
reduce hospitalizations need to focus on retention in care,
adherence, and preventing active TB. ART reduces TB inci-
dence by 65% in HIV-infected people,44 underlining the need to
ensure optimal functioning ART programmes in high TB
burden communities. Also, isoniazid preventive therapy in
patients on ART reduces TB incidence by 37%.45 Comprehen-
sive integration of ART and TB services is also a priority. Third,
hospital-based surveillance provides an important indicator of
the conditions contributing to morbidity and mortality in ART
programmes and programme deficiencies. It provides similar
information to monitoring causes of death at a broader level
without the difficulties of determining mortality attribution in
the community and with more accurate diagnostic information.
With the WHO now advising ART for all HIV-infected people
at diagnosis regardless of CD4 count,46 it can be anticipated that
numbers of patients requiring ARTwill increase substantially in
the next few years, adding to the challenges faced by ART
services in addressing the ‘‘cracks’’ we identified.
Study strengths were the inclusion of an unselected cross-
sectional cohort of patients tominimize selection bias, systematic
screening for TB in all participants, and our ability to establish a
diagnosis in almost all patients (99.5%). Vital status at 90 days
was ascertained in approximately 95% of patients. There are
limitations to our study. This was a single center study. However,
we believe the results are generalizable to other inpatient settings
in South Africa as this study was conducted at a district hospital
similar to hospitals found across South Africa, and the HIV
seroprevalence in surrounding communities is similar to national
seroprevalence.However,ARTcoverage inWesternCape is high
and in settings with lower coverage, hospital-related morbidity
andmortality may well be even higher. The study was performed
at a hospital level without robust data regarding the denominator
population meaning we were unable to calculate reliable inci-
dence rates for the broader HIV population. Some patients who
reported not currently being on ART were virologically sup-
pressed. This could be due to misclassification, laboratory tech-
nical issues, or clinical factors (recently interrupted ART or elite
or post-treatment controllers). Patients admitted with known
drug-resistant TB were typically admitted to separate isolation
rooms and not enrolled.
In conclusion, despite widespread ART availability in sur-
rounding communities, HIV still contributed to over 60% of
medical admissions to this South African hospital. One-third of
patients required hospital readmission and mortality approached
15% at 90 days. This is a substantial resource burden for over-
stretched health services. TB was the most common primary
clinical diagnosis and leading cause of death. ‘‘Cracks’’ at points
throughout the HIV care cascade were key drivers. Additional
interventions are required within the HIV programme to reduce
these admissions. Several such interventions have been proposed,
and have or are being evaluated.39,40,47–50
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